Insulin aspart Sanofi

RSS

insulin aspart

Authorised
This medicine is authorised for use in the European Union.

Overview

Insulin aspart Sanofi is a medicine used to control blood glucose (sugar) levels in patients from one year of age who have diabetes.

Insulin aspart Sanofi is a ‘biosimilar medicine’. This means that Insulin aspart Sanofi is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Insulin aspart Sanofi is NovoRapid.

Insulin aspart Sanofi contains the active substance insulin aspart, a rapid-acting insulin.

This EPAR was last updated on 07/07/2020

Authorisation details

Product details
Name
Insulin aspart Sanofi
Agency product number
EMEA/H/C/005033
Active substance
insulin aspart
International non-proprietary name (INN) or common name
insulin aspart
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AB05
BiosimilarBiosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Publication details
Marketing-authorisation holder
sanofi-aventis groupe
Date of issue of marketing authorisation valid throughout the European Union
25/06/2020
Contact address

54 rue La Boetie
75008 Paris
France

Product information

25/06/2020 Insulin aspart Sanofi - EMEA/H/C/005033 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Assessment history

How useful was this page?

Add your rating